Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce D Wyse

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Pharmacology, Biochemistry, and Behavior|March 19, 2013
Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methodsArjun Muralidharan, Bruce D Wyse, Maree T Smith
Pain Medicine (Malden, Mass.)|January 18, 2014
Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist in a rat model of prostate cancer-induced bone painArjun Muralidharan, Bruce D Wyse, Maree T Smith
Behavioural Pharmacology|October 18, 2014
Optimization and pharmacological characterization of a refined cisplatin-induced rat model of peripheral neuropathic painFelicity Yaqin Han, Bruce D Wyse, Maree T Smith
Pain Medicine (Malden, Mass.)|March 16, 2013
Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in ratsMaree T Smith, Bruce D Wyse, Stephen R Edwards
Clinical and Experimental Pharmacology & Physiology|April 2, 2019
Nitric oxide modulates μ-opioid receptor function in vitroLillian Huang, Bruce D Wyse, Craig M Williams, et al.
Clinical and Experimental Pharmacology & Physiology|November 2, 2007
Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley ratSamuel Chan, Stephen R Edwards, Bruce D Wyse, et al.
Pain Medicine (Malden, Mass.)|February 22, 2011
Longitudinal study of painful diabetic neuropathy in the Zucker diabetic fatty rat model of type 2 diabetes: impaired basal G-protein activity appears to underpin marked morphine hyposensitivity at 6 monthsKathleen J Otto, Bruce D Wyse, Peter J Cabot, et al.
Pain Medicine (Malden, Mass.)|April 13, 2011
Insulin implants prevent the temporal development of mechanical allodynia and opioid hyposensitivity for 24-wks in streptozotocin (STZ)-diabetic Wistar ratsKathleen J Otto, Bruce D Wyse, Peter J Cabot, et al.
Pain Medicine (Malden, Mass.)|June 8, 2013
A small molecule angiotensin II type 2 receptor (AT₂R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root gangliaMaree T Smith, Trent M Woodruff, Bruce D Wyse, et al.
Clinical and Experimental Pharmacology & Physiology|June 30, 2015
The furoxan nitric oxide donor, PRG150, evokes dose-dependent analgesia in a rat model of painful diabetic neuropathyLillian Y Huang, Debbie Y Tsui, Craig M Williams, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Pharmacology, Biochemistry, and Behavior|March 19, 2013
Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methodsArjun Muralidharan, Bruce D Wyse, Maree T Smith
Pain Medicine (Malden, Mass.)|January 18, 2014
Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist in a rat model of prostate cancer-induced bone painArjun Muralidharan, Bruce D Wyse, Maree T Smith
Behavioural Pharmacology|October 18, 2014
Optimization and pharmacological characterization of a refined cisplatin-induced rat model of peripheral neuropathic painFelicity Yaqin Han, Bruce D Wyse, Maree T Smith
Pain Medicine (Malden, Mass.)|March 16, 2013
Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in ratsMaree T Smith, Bruce D Wyse, Stephen R Edwards
Clinical and Experimental Pharmacology & Physiology|April 2, 2019
Nitric oxide modulates μ-opioid receptor function in vitroLillian Huang, Bruce D Wyse, Craig M Williams, et al.
Clinical and Experimental Pharmacology & Physiology|November 2, 2007
Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley ratSamuel Chan, Stephen R Edwards, Bruce D Wyse, et al.
Pain Medicine (Malden, Mass.)|February 22, 2011
Longitudinal study of painful diabetic neuropathy in the Zucker diabetic fatty rat model of type 2 diabetes: impaired basal G-protein activity appears to underpin marked morphine hyposensitivity at 6 monthsKathleen J Otto, Bruce D Wyse, Peter J Cabot, et al.
Pain Medicine (Malden, Mass.)|April 13, 2011
Insulin implants prevent the temporal development of mechanical allodynia and opioid hyposensitivity for 24-wks in streptozotocin (STZ)-diabetic Wistar ratsKathleen J Otto, Bruce D Wyse, Peter J Cabot, et al.
Pain Medicine (Malden, Mass.)|June 8, 2013
A small molecule angiotensin II type 2 receptor (AT₂R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root gangliaMaree T Smith, Trent M Woodruff, Bruce D Wyse, et al.
Clinical and Experimental Pharmacology & Physiology|June 30, 2015
The furoxan nitric oxide donor, PRG150, evokes dose-dependent analgesia in a rat model of painful diabetic neuropathyLillian Y Huang, Debbie Y Tsui, Craig M Williams, et al.
Pageof 2